Cancer cells and normal cells are known to respond differently to nutrients
and drugs that affect glutathione status.
Numerous studies have shown that tumor cells have elevated levels of glutathione
levels, which confers resistance to chemotherapy drugs.
One of the challenges of cancer therapy is how to deplete tumor cells of
glutathione, so as to make them more vulnerable to the effects of chemotherapy
drugs, while at the same time allowing normal cells to remain relatively
unaffected by chemotherapeutic drugs.
A number of new findings have emerged that take into consideration the role
of glutathione in pathways that promote programmed cell death (apoptosis)
in cancer cells.
A German study has reported that glutathione (GSH) plays a critical role
in cellular mechanisms that result in cell death. The study found that cancer
cells resistant to apoptosis had higher intracellular GSH levels.
Depletion of glutathione in these tumor cells made them more vulnerable to
the effects of anticancer drugs or the gene that promotes apoptosis (CD95
or APO-1/Fas). The researchers concluded that apoptosis resistance in tumor
cells depends, at least in part, on intracellular GSH levels. (1)
In another study conducted in Spain, researchers found that lowering GSH
concentration may be convenient not only for the efficiency of chemotherapy,
but also to induce a rather fast and direct apoptosis mechanism in tumor
cells. (2)
Based on that premise that the glutathione-S-transferase enzyme is expressed
at high levels in many tumors, researchers at the Fox Chase Cancer Center
in Pennsylvania, went on to design a novel prodrug (PABA/NO).
The glutathione-s-transferase in tumor cells converts PABA/NO to lethal nitric
oxide, resulting in death of the tumor cell. The prodrug was shown to have
antitumor effects in an animal model for human ovarian cancer. (3)
In the fourth study, Polish researchers found that ingesting a selenium
supplement is beneficial, as a supportive element in chemotherapy. (4)
Selenium is a co-factor of the enzyme glutathione peroxidase [GSH-P(x)] and
was found to significantly increase the activity of GSH-P(x) in patients
reciving the supplement.
A previous clinical study by the same researchers recommended the administration
of selenium in patients with ovarian cancer undergoing multi-drug chemotherapy.
(5)
Another interesting study by researchers in Texas showed that your chances
of surviving a type of brain cancer, called primary malignant glioma, could
depend on the type of glutathione-s-transferase (GST) gene you were born
with.
Having a combination of a two specific variants of GST (germ-line GSTP1*A/*A
and GSTM1 null genotype) confers a survival advantage in some types of brain
cancers, but also comes with an increased risk of adverse events related
to chemotherapy. (6)
There is compelling evidence to suggest a crucial role for glutathione and
substances that target glutathione metabolism in the prevention and treatment
of cancer.
Undenatured whey protein is one of the natural foods known to selectively
deplete cancer cells of their glutathione, thus making them more susceptible
to such cancer treatments as radiation and chemotherapy.
For a complete report on the research on undenatured whey protein and cancer
see the report Glutathione (GSH) and Whey Protein in Cancer.
Disclaimer: The information here is not provided by medical professionals
and is not intended as a substitute for medical advice. Please consult your
physician before beginning any course of treatment.
References:
1. Friesen C et al. [Cell Death and Differentiation advance online publication,
23 April 2004]
2. Tormos C et al. [Cancer Lett. 2004 May 10;208(1):103-13.]
3. Findlay VJ et al. [Mol Pharmacol. 2004 May;65(5):1070-9.]
4. Sieja K et al. [Gynecol Oncol. 2004 May;93(2):320-327.]
This article was first published in the April 2004 issue of The Glutathione
Report,
http://www.glutathione-report.com,
a newsletter featuring regular updates on the health benefits of glutathione.
Get a Free report on Glutathione in Health and Disease
http://www.1whey2health.com
DISCLAIMER
- Please note that all articles on this web site does not constitute
professional advice. All articles are intended to provide a general view
of many topical subjects from a variety of sources. We are not responsible
for the content or any sponsored links that you may choose to visit from
this web site. We suggest you to consult a solicitor and your doctor for
advice relevant to you own situation before making any important decisions.
The author is not an expert in any given field. By printing, downloading,
or using you agree to our full terms. Below is a summary of some of the terms.
If you do not agree to the full terms, do not use the information. We are
only publishers of this material, not authors. Information may have errors
or be outdated. Some information is from historical sources or represents
opinions of the author. It is for research purposes only. The information
is "AS IS", "WITH ALL FAULTS". User assumes all risk of use, damage, or injury.
You agree that we have no liability for any damages. We are not liable for
any consequential, incidental, indirect, or special damages. You indemnify
us for claims caused by you.